Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Burges

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Annals of Surgical Oncology|September 30, 2006
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trialPhilipp Harter, Andreas du Bois, Maik Hahmann, et al.
Journal of Surgical Oncology|March 28, 2023
Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT databaseMaximilian Klar, Helmut Plett, Philipp Harter, et al.
International Journal of Molecular Sciences|February 24, 2024
Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer CenterFabian B T Kraus, Elena Sultova, Kathrin Heinrich, et al.
Iscience|December 16, 2025
Organoid platinum-resistance model identifies KRT17 as a biomarker of targeted therapy in ovarian cancerJuliane Reichenbach, Juliana Schmid, Sophia Hierlmayer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2011
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITOPhilipp Harter, Jalid Sehouli, Alexander Reuss, et al.
Frontiers in Oncology|June 4, 2026
Real-world data on the clinical impact of molecular tumor boards in high- and low-grade serous ovarian cancerFabian B T Kraus, Elena Benkel, Jörg Kumbrink, et al.
Journal of Surgical Oncology|March 9, 2026
Fertility-Sparing Surgery, Treatment Strategies and Survival of Women With Malignant Ovarian Germ Cell Tumours-A Descriptive Analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie CORSETT DatabaseMaximilian Klar, Malak Moubarak, Philipp Harter, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|March 1, 2019
Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics DimensionsBoris Winterhoff, Stefan Kommoss, Florian Heitz, et al.
JCO Precision Oncology|June 12, 2026
Constitutional <i>BRCA1</i> Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 StudyMohamad Kayali, Eric Hahnen, Alexander Burges, et al.
Archives of Gynecology and Obstetrics|April 12, 2020
Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study GroupUlrich Canzler, Hans-Joachim Lück, Petra Neuser, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Annals of Surgical Oncology|September 30, 2006
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trialPhilipp Harter, Andreas du Bois, Maik Hahmann, et al.
Journal of Surgical Oncology|March 28, 2023
Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT databaseMaximilian Klar, Helmut Plett, Philipp Harter, et al.
International Journal of Molecular Sciences|February 24, 2024
Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer CenterFabian B T Kraus, Elena Sultova, Kathrin Heinrich, et al.
Iscience|December 16, 2025
Organoid platinum-resistance model identifies KRT17 as a biomarker of targeted therapy in ovarian cancerJuliane Reichenbach, Juliana Schmid, Sophia Hierlmayer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2011
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITOPhilipp Harter, Jalid Sehouli, Alexander Reuss, et al.
Frontiers in Oncology|June 4, 2026
Real-world data on the clinical impact of molecular tumor boards in high- and low-grade serous ovarian cancerFabian B T Kraus, Elena Benkel, Jörg Kumbrink, et al.
Journal of Surgical Oncology|March 9, 2026
Fertility-Sparing Surgery, Treatment Strategies and Survival of Women With Malignant Ovarian Germ Cell Tumours-A Descriptive Analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie CORSETT DatabaseMaximilian Klar, Malak Moubarak, Philipp Harter, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|March 1, 2019
Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics DimensionsBoris Winterhoff, Stefan Kommoss, Florian Heitz, et al.
JCO Precision Oncology|June 12, 2026
Constitutional <i>BRCA1</i> Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 StudyMohamad Kayali, Eric Hahnen, Alexander Burges, et al.
Archives of Gynecology and Obstetrics|April 12, 2020
Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study GroupUlrich Canzler, Hans-Joachim Lück, Petra Neuser, et al.
Pageof 12